Curated News
By: NewsRamp Editorial Staff
August 07, 2026

Lantern Pharma to Host Q2 2026 Webcast on AI-Driven Oncology Progress

Discuss on LinkedIn Discuss on X, formerly Twitter Discuss on Substack Discuss on Telegram participate in discussion on bluesky Participate in discussion on Mastodon View History of this news story on GitHub
Original Source

TLDR

  • Lantern Pharma's Q2 2026 webcast offers investors early access to clinical and AI platform updates, potentially revealing strategic advantages.
  • Lantern Pharma will detail Q2 2026 results and progress of RADR and Open-Medicine AI platforms during the Aug. 14 webcast.
  • Lantern Pharma's AI-driven oncology research aims to accelerate cancer therapy development, bringing hope to patients awaiting new treatments.
  • Lantern Pharma's new AI co-scientist platform, withZeta.ai, is now commercially available, marking a novel revenue stream.

Impact - Why it Matters

This news is significant for investors and the oncology community because Lantern Pharma is at the forefront of using artificial intelligence to accelerate cancer drug development. The webcast will provide insights into the company's financial health and clinical advancements, which could influence investment decisions and offer hope for new treatments. The commercial availability of withZeta.ai also signals a shift towards AI-powered drug discovery, potentially reducing costs and time in bringing therapies to patients. For those tracking precision oncology and AI in healthcare, this update is crucial for understanding market trends and future treatment options.

Summary

Lantern Pharma (NASDAQ: LTRN), a clinical-stage precision oncology company leveraging artificial intelligence, has announced a webcast to discuss its second-quarter 2026 operating and financial results. The event, scheduled for August 14, 2026, at 9 a.m. ET, will feature President and CEO Panna Sharma along with members of the management team. They will review results for the quarter ended June 30, 2026, and provide updates on upcoming milestones, clinical trials, and developments involving the company's RADR(R) and Open-Medicine AI platforms. A replay will be available on the company's investor relations website.

Lantern Pharma is known for its proprietary RADR(R) platform, which uses AI and machine learning to transform cancer therapy development. The company's clinical pipeline includes LP-184 (acylfulvene), LP-284 (a TC-NER targeting compound for hematologic and solid tumors), and LP-300 (a cisplatin/ethacraplatin analog) being evaluated in the HARMONIC Phase 2 trial for never-smoker patients with relapsed advanced lung adenocarcinoma. LP-184 is also under development for pediatric CNS cancers through Starlight Therapeutics, a wholly owned subsidiary. Additionally, Lantern has launched withZeta.ai, a multi-agentic AI co-scientist platform now commercially available as a subscription-based research platform, representing a new revenue stream. The company operates an AI Center of Excellence in Bengaluru, India, and is headquartered in Dallas, Texas.

InvestorWire (IW), a specialized communications platform, distributed this press release. IW is part of the Dynamic Brand Portfolio @ IBN, offering wire-grade press release syndication, editorial syndication to 5,000+ outlets, enhanced press release services, social media distribution, and tailored corporate communications solutions. For more information, visit InvestorWire. The full press release is available at https://ibn.fm/l80kv.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Lantern Pharma to Host Q2 2026 Webcast on AI-Driven Oncology Progress

blockchain registration record for this content.